FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
ABBVAbbVie(ABBV) ZACKS·2024-06-28 00:06

AbbVie (ABBV) announced that the FDA approved its lymphoma drug Epkinly (epcoritamab) for a second indication — follicular lymphoma (FL). The drug has been developed in partnership with Genmab (GMAB) .The FDA approved Epkinlyunder the accelerated pathway to treat adults with relapsed or refractory (R/R) FL after two or more lines of therapies. The agency initially granted accelerated approval to the drug last year to treat patients with R/R diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphom ...